ASX Top 200 Stocks Down Under 9 May 2022: Healius (ASX:HLS)

Healius: It’s not just a one-trick pony

Pathology is one of the most important branches of medicine, accounting for 70% of all healthcare decisions. Amidst the pandemic it has boomed because of COVID-19 testing but even that came at the expense of other services. Healius is not the only pathology stock on the ASX but we are most bullish on it because it’s ‘landing’ back to normality will be softer than its peers because it offered a broader range of services including day surgery and radiology.

Click here to read the previous edition of ASX Top 200 Stocks Down Under published 2 May 2022

For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter.